3 SEHK Growth Stocks With High Insider Ownership Expecting Up To 55% Earnings Growth

In This Article:

The Hong Kong market has been experiencing mixed performance, with the Hang Seng Index declining by 0.45% amid weak manufacturing data and cautious investor sentiment. Despite these challenges, growth companies with high insider ownership can offer promising opportunities for investors looking to capitalize on robust earnings potential. In this article, we will explore three SEHK growth stocks that are not only demonstrating strong earnings growth expectations but also benefit from significant insider ownership, which often aligns management interests with those of shareholders.

Top 10 Growth Companies With High Insider Ownership In Hong Kong

Name

Insider Ownership

Earnings Growth

iDreamSky Technology Holdings (SEHK:1119)

18.8%

104.1%

Pacific Textiles Holdings (SEHK:1382)

11.2%

37.7%

Tian Tu Capital (SEHK:1973)

34%

70.5%

Fenbi (SEHK:2469)

31.1%

42.8%

Adicon Holdings (SEHK:9860)

22.4%

28.3%

Zylox-Tonbridge Medical Technology (SEHK:2190)

18.7%

79.3%

DPC Dash (SEHK:1405)

38.2%

91.4%

Biocytogen Pharmaceuticals (Beijing) (SEHK:2315)

13.9%

100.1%

Ocumension Therapeutics (SEHK:1477)

23.3%

93.7%

Beijing Airdoc Technology (SEHK:2251)

28.6%

83.9%

Click here to see the full list of 54 stocks from our Fast Growing SEHK Companies With High Insider Ownership screener.

Let's uncover some gems from our specialized screener.

SSY Group

Simply Wall St Growth Rating: ★★★★☆☆

Overview: SSY Group Limited researches, develops, manufactures, trades in, and sells various pharmaceutical products to hospitals and distributors in China and internationally, with a market cap of HK$11.22 billion.

Operations: The company's revenue segments include HK$6.30 billion from Intravenous Infusion Solution and Others, and HK$387.45 million from Medical Materials.

Insider Ownership: 10.4%

Earnings Growth Forecast: 15% p.a.

SSY Group, a growth company with high insider ownership in Hong Kong, is forecast to grow earnings by 15.03% annually, outpacing the Hong Kong market's 11.3%. Trading at 76.2% below its estimated fair value and expected to rise by 64.7%, it has recently secured multiple drug production approvals from China's NMPA, enhancing its portfolio with treatments for Parkinson's disease and depression among others. However, its dividend of 4.5% isn't well covered by free cash flows.

SEHK:2005 Ownership Breakdown as at Aug 2024

MGM China Holdings

Simply Wall St Growth Rating: ★★★★☆☆

Overview: MGM China Holdings Limited is an investment holding company that develops, owns, and operates gaming and lodging resorts in the Greater China region with a market cap of HK$44.61 billion.